Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.

Abstract

RATIONALE:

Patients with relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have poor prognosis. Many patients are not eligible for 2nd HSCT due to organ dysfunction or other complications that prevent them from tolerating conditioning chemotherapy. In those ineligible patients for 2nd HSCT with myeloablative conditioning regimen, reduced intensity conditioning (RIC) are often used. RIC regimens are less toxic but has a less direct anti-tumor efficacy so that RIC regimens are not suitable for the patients with high tumor burden. To overcome this dilemma, Gemtuzumab Ozogamicin (GO) has been used as a part of RIC regimens to add anti-tumor efficacy. We report here a relapsed AML patient who was treated with GO monotherapy followed by stem cell infusion.

PATIENT CONCERNS:

A 25-year-old male with AML experienced relapse 9 months after allo-HSCT.

DIAGNOSIS:

Since he had mild renal and cardiac dysfunction and his AML did not progress rapidly, we decided not to give him an intensive chemotherapy. However, after azacitidine (AZA) and donor lymphocyte infusion therapy, his leukemic blasts did not decrease.

INTERVENTIONS:

Originally, we had planned to proceed with a 2nd allo-HSCT with RIC regimen that consisted of fludarabine, melphalan and fractionated GO (3 mg/m/dose) on day -21, -18, and -15. However, the patient developed appendicitis after the last dose of GO when his neutrophil was 0 cells/μl. Based on his medical acuity, we terminated the rest of the patients conditioning regimen and the patient did not receive any further chemotherapeutics. The patient was still infused with peripheral blood stem cells from the donor on day 0.

OUTCOMES:

His appendicitis was resolved by antibiotics without surgery. His AML has been in CR more than 18 months under AZA maintenance therapy.

LESSONS:

GO monotherapy could be a conditioning regimen of 2nd allo HSCT from the same donor as the first HSCT for relapsed AML patients.

• Authors: Ritsu Sumiyoshi, Haruko Tashiro, Sumiko Saito, Takuji Matsuo, Tadashi Yamamoto, Kensuke Matsumoto, Jun Ooi, Naoki Shirafuji
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 35 Pg. e22064 (Aug 28 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 32871966 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Immunological
• Gemtuzumab

Topics

• Adult
• Antineoplastic Agents, Immunological (therapeutic use)
• Gemtuzumab (therapeutic use)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute (therapy)
• Male
• Recurrence
• Transplantation, Homologous